Multivitamin may shield ozempic users from hidden nutrient shortages

NCT ID NCT06981936

Recruiting now Disease control Sponsor: General Committee of Teaching Hospitals and Institutes, Egypt Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether a daily multivitamin tablet can prevent vitamin and mineral deficiencies in people using GLP-1 drugs (like Ozempic or Saxenda) for weight loss. These drugs suppress appetite, which can lead to low nutrient intake. The trial will compare a multivitamin to a placebo over 12 months in 150 adults with obesity. Researchers will measure blood nutrient levels to see if the supplement helps maintain healthy levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Balance Tablet (multivitamin and mineral supplement)
What this could lead to: If it works, this could show that taking a daily multivitamin helps prevent nutrient deficiencies in people using GLP-1 drugs for weight loss.
What could go wrong: This is a relatively small, early-phase trial. The supplement may not prevent all deficiencies, and results may not apply to everyone. There is little risk from the supplement itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICRONUTRIENT DEFICIENCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder Weight Loss nutritional deficiency disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MICRONUTRIENT DEFICIENCIES

Contacts and locations

Locations

Facility Name: The surgical department of Medical Research Institute Hospital, Alexandria University, Alexandria, Facility
RECRUITING

Alexandria, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.